[Myelodysplastic syndromes: treatment strategy up-to-date].
Kaoru
K
Tohyama
D000961:Antilymphocyte Serum / Q000008:administration & dosage; D001374:Azacitidine / Q000008:administration & dosage; D001565:Benzoates / Q000008:administration & dosage; D016572:Cyclosporine / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D000077588:Deferasirox; D018450:Disease Progression; D055808:Drug Discovery / Q000639:trends; D004359:Drug Therapy, Combination; D004921:Erythropoietin / Q000008:administration & dosage; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D007502:Iron Chelating Agents / Q000008:administration & dosage; D000077269:Lenalidomide; D015470:Leukemia, Myeloid, Acute / Q000209:etiology / Q000517:prevention & control; D009190:Myelodysplastic Syndromes / Q000145:classification* / Q000175:diagnosis / Q000628:therapy*; D011788:Quality of Life; D018570:Risk Assessment; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives; D014230:Triazoles / Q000008:administration & dosage
D000961:Antilymphocyte Serum; D001565:Benzoates; D007166:Immunosuppressive Agents; D007502:Iron Chelating Agents; D014230:Triazoles; D003561:Cytarabine; D004921:Erythropoietin; D016179:Granulocyte Colony-Stimulating Factor; D013792:Thalidomide; D016572:Cyclosporine; D000077269:Lenalidomide; D001374:Azacitidine; D000077588:Deferasirox; D015255:Idarubicin